|
LAPNet1: Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma. |
| |
|
Consulting or Advisory Role - Alpha Tau; AstraZeneca; BMS GmbH & Co. KG; MSD; Netris Pharma; SERVIER |
Speakers' Bureau - AstraZeneca; Incyte; Merck; MSD; Pierre Fabre; SERVIER |
Research Funding - GenoScience Pharma (Inst); Netris Pharma (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Pierre Fabre; SERVIER |
| |
|
Consulting or Advisory Role - AstraZeneca; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER; Takeda; Viatris |
Travel, Accommodations, Expenses - Pierre Fabre; SERVIER |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Bayer Schering Pharma; Eisai; INCYTE; IPSEN; Roche; SERVIER |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; IPSEN; ROCHE; SERVIER; Taiho Pharmaceutical; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - AstraZeneca; IPSEN; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; AstraZeneca; Bayer; Merck Serono; MSD Oncology; Pierre Fabre; SERVIER; Takeda; Takeda; Viatris |
Consulting or Advisory Role - Abbvie; Acobiom; Amgen; Bayer; BMS; GlaxoSmithKline; Incyte; Merck Serono; MSD; Servier; Takeda |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche; Sanofi; Servier |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Amgen; Apmonia Therapeutics; Astellas Pharma; Deciphera; MSD Oncology; Pierre Fabre; SERVIER; Takeda |
Speakers' Bureau - Amgen; Deciphera; Merck Serono; MSD Oncology; Pierre Fabre; Servier |
Travel, Accommodations, Expenses - Pierre Fabre; Servier; Takeda |
| |
|
Stock and Other Ownership Interests - Netris Pharma |
Patents, Royalties, Other Intellectual Property - Netris Pharma |
| |
|
Honoraria - AstraZeneca; Incyte; MSD Oncology; SERVIER |
Travel, Accommodations, Expenses - MSD Oncology |